1

Sonoma Pharmaceuticals

#10371

Rank

$5.07M

Marketcap

US United States

Country

Sonoma Pharmaceuticals
Leadership team

Ms. Amy M. Trombly (CEO, Pres & Director)

Mr. Bruce Thornton (COO & Corp. Sec.)

Mr. Jerome Dvonch (Exec. Officer)

Products/ Services
Health Care
Headquarters
Petaluma, California, United States
Established
1999
Company Registration
SEC CIK number: 0001367083
Revenue
5M - 20M
Traded as
SNOA
Social Media
Overview
Location
Summary
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
History

Founded in 2010, Sonoma Pharmaceuticals ®, Inc. (“Sonoma” or the “Company”) is a specialty healthcare company that develops and markets unique and effective solutions for the treatment of dermatological conditions

Mission
Our mission is to improve the quality of patient care and satisfaction by providing innovative, high-quality products that address skin conditions and promote healthy skin in an efficient and cost-effective manner.
Vision
Our vision is to be a trusted partner in providing leading-edge skin care products to the worldwide medical community.
Key Team

Mr. Chad White (Interim Chief Financial Officer)

Dr. Robert Northey (Exec. VP of R&D)

Ms. Victoria Covel (Assistant Controller)

Recognition and Awards
In 2018, Sonoma’s CELSIUS Non-Aerosol Spray was a recipient of the prestigious Red Dot Award in the Product Design category.
References

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Sonoma Pharmaceuticals
Leadership team

Ms. Amy M. Trombly (CEO, Pres & Director)

Mr. Bruce Thornton (COO & Corp. Sec.)

Mr. Jerome Dvonch (Exec. Officer)

Products/ Services
Health Care
Headquarters
Petaluma, California, United States
Established
1999
Company Registration
SEC CIK number: 0001367083
Revenue
5M - 20M
Traded as
SNOA
Social Media